On Thursday (October 4) new details were revealed on the joint venture between a Canadian licensed producer (LP) and beverage company Molson Coors Brewing (NYSE:TAP;TSX:TAP).

The alcohol company and HEXO (TSX:HEXO) unveiled the partnership between the two as it seeks to develop cannabis infused beverages for the recreational market. The joint venture, called Truss, will have former Molson executive Brett Vye act as CEO.


“When consumable cannabis is legalized in Canada, Truss will be ready to make its mark as a responsible leader in providing high-quality beverages for the Canadian consumer,” Vye said in a press release.

The joint venture was first announced in August, with Molson taking a 57.5 percent controlling stake and HEXO, formerly known as Hydropothecary, gaining the remaining 42.5 percent.

Sebastien St-Louis, CEO of HEXO, will get a seat in the board of directors. As part of the transaction between the two companies closing, HEXO issued 11.5 million warrants to the Canadian division of Molson. These shares are excerisable to buy one HEXO share for a price of C$6.

“While we remain a beer business at our core, we are excited to create a separate new venture with a trusted partner that will be a market leader in offering Canadian consumers new experiences with quality, reliable and consistent non-alcoholic, cannabis-infused beverages,” Frederic Landtmeters, president and CEO of Molson Coors Canada, said when the partnership was first unveiled.

These infused beverages have become a trend item of investment from cannabis producers and now beverage companies join other established seeking entries into the emerging cannabis space.

On Tuesday (October 2), Hugh Johnston, chief financial officer (CFO) of PepsiCo (NASDAQ:PEP) said the beverage company will be taking a critical look at the cannabis market. However, no deals were in place at the time.

The Coca-Cola Company (NYSE:KO) was forced to issue a statement in response to a report from BNN Bloomberg showing the soft drinks giant was in the final stages of a deal with Aurora Cannabis (TSX:ACB).

“Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world. The space is evolving quickly. No decisions have been made at this time,” Coca-Cola said.

HEXO faces criticism from large investor

In September a letter from Riposte Capital, a company claiming to be the second largest public shareholder of HEXO, was made public demanding the company take critical steps to increase the value of its stock.

The letter even suggested for management to consider selling the company. In its letter, Riposte Capital estimated HEXO’s joint venture “could be worth multiples of the current market capitalization of HEXO today.”

One of the suggestions for action to take by HEXO included obtaining a “meaningful direct investment” from the alcohol partner. “In lieu of your pending proposal to issue warrants with a $6 strike, consider a direct placement for up to 20 percent of the equity at current levels in order to underpin the balance sheet and solidify distribution partnership,” the letter indicated.

Investor takeaway

Infused beverages, alongside edibles, will not be allowed in Canada at the start of legalization on October 17. However, the interest from these alcohol companies is clear to form partnerships and, in the case of Molson, participate in the creation of a new product.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less